Therapeutic Plasma Exchange Is Estimated to Witness High Growth Owing to Opportunity of Improving Diseases Treatment Effectiveness

Therapeutic Plasma Exchange Is Estimated to Witness High Growth Owing to Opportunity of Improving Diseases Treatment Effectiveness

Clinical diagnostics involves disease management and prevention through tests and procedures conducted to detect, diagnose, monitor, and treat diseases. It plays a pivotal role in healthcare by aiding early detection of diseases to enable prompt treatment and intervention. Rapid advancements in biotechnology have transformed clinical diagnostics over the past decade, with liquid biopsy techniques revolutionizing early cancer screening and management. Liquid biopsy allows for non-invasive detection of cancer biomarkers such as circulating tumor DNA, circulating tumor cells, and exosomes in blood. This has enabled genomic profiling of cancers without the need for invasive surgical tumor biopsies.

The global clinical diagnostic market is estimated to be valued at US$ 83.34 Bn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The key driver accentuating market growth is the expanding applications of liquid biopsy technology in cancer screening and monitoring. Liquid biopsy tests provide real-time insights into tumor profiles and enable detection of resistance markers that help personalize treatment plans. This reduces healthcare costs associated with repeat invasive biopsies and improves patient outcomes. Additionally, increasing adoption of point-of-care testing is boosting market expansion. POC testing facilitates immediate clinical decision making and has high potential in resource-limited settings. Furthermore, integration of AI and machine learning into diagnostic platforms is augmenting their efficacy and fueling market revenue. However, lack of skilled professionals and high costs associated with advanced diagnostic procedures may impede market growth over the forecast period.

SWOT Analysis

Strength: The Global Clinical Diagnostic Market Size has strong capabilities in disease detection and diagnosis. Advanced technologies enable accurate and quick diagnosis of various diseases. Further, rising awareness among patients regarding early diagnosis is driving demand for clinical diagnostic services.

Weakness: High costs associated with advanced diagnostic equipment and techniques can limit their widespread adoption. Additionally, shortage of skilled laboratory technicians poses challenges.

Opportunity: Growing geriatric population prone to various diseases creates opportunities for clinical diagnostic players. Furthermore, rising incidence of chronic diseases will augment the need for diagnostic testing. Untapped opportunities exist in developing regions.

Threats: Stringent regulations surrounding diagnostic services increase compliance costs. Further, reimbursement issues and intense competition from existing and new entrants pose threats.

Key Takeaways

The global clinical diagnostic market is expected to witness high growth over the forecast period. The market size for clinical diagnostic was valued at US$ 83.34 billion in 2023, registering a CAGR of 15% during the forecast period.

Regional analysis

North America currently dominates the clinical diagnostic market owing to advanced healthcare infrastructure and high healthcare spending. The region accounts for over 35% revenue share helped by the presence of leading players. Asia Pacific clinical diagnostic market is poised to grow at fastest pace supported by rising medical tourism, increasing healthcare expenditure and large patient pool. China dominates the APAC clinical diagnostic market with over 20% value share in 2023.

Key players

Key players operating in the clinical diagnostic market are Vivostat A/S, Estar Medical, CosmoFrance Inc., Kelly Harris Aesthetics, Arthrex, Inc., Terumo Corporation, T-Biotechnology Ltd. St., EmCyte Corporation, Johnson & Johnson Private Limited, Zimmer Biomet, PRP Concepts, ADVACARE PHARMA, Isto Biologics, Arthrex, Inc. and Stryker. Major players are focusing on new product launches, expansion strategies to strengthen their market presence.

Get More Insights On This Topic:

Editorial Team